Insights from clinical research completed during the west Africa Ebola virus disease epidemic

The Lancet Infectious Diseases

Volumn 17, Issue 9, 2017, Pages e280-e292

  Rojek, Amanda ^a   Horby, Peter ^a   Dunning, Jake ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE;

ACUTE DISEASE; AFRICA; BRADYCARDIA; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COMPLICATION; DYSPNEA; EBOLA HEMORRHAGIC FEVER; GASTROINTESTINAL DISEASE; HUMAN; HYPERKALEMIA; INFLAMMATION; KIDNEY DYSFUNCTION; LIVER INJURY; MIXED INFECTION; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SUPPORTIVE CARE; SURVIVOR; TACHYPNEA; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; MEDICAL RESEARCH; MORTALITY; TIME FACTOR; TRANSMISSION;

AFRICA, WESTERN; BIOMEDICAL RESEARCH; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MORTALITY; TIME FACTORS;

EID: 85018340356     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30234-7     Document Type: Review

References (136)

1. Baize, S, Pannetier, D, Oestereich, L, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371 (2014), 1418–1425.
2. WHO. Statement on the 1st meeting of the IHR Emergency Committee on the 2014 Ebola outbreak in west Africa. http://www.who.int/mediacentre/news/statements/2014/ebola-20140808/en/, 2014 (accessed March 1, 2016).
3. WHO. Ebola situation report. http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016, 30 March 2016 (accessed March 30, 2016).
4. UN Economic Commission for Africa. Socio-economic impacts of Ebola on Africa (Revised edition). http://www.uneca.org/sites/default/files/PublicationFiles/eca_ebola_report_final_eng_0.pdf, 2015 (accessed Oct 11, 2016).
5. Parpia, AS, Ndeffo-Mbah, ML, Wenzel, NS, Galvani, AP, Effects of response to 2014–2015 Ebola outbreak on deaths from malaria, HIV/AIDS, and tuberculosis, west Africa. Emerg Infect Dis 22 (2016), 433–441.
6. WHO. Ebola situation reports, December 17, 2014. http://apps.who.int/ebola/en/status-outbreak/situation-reports/ebola-situation-report-17-december-2014, 2016 (accessed April 4, 2016).
7. WHO. Ebola response roadmap. http://www.who.int/csr/resources/publications/ebola/response-roadmap/en/, 2014 (accessed Sept 1, 2016).
8. WHO. How can science inform our response to Ebola virus disease? October 7, 2014. http://www.who.int/csr/resources/publications/ebola/science-ebola-response/en/, 2014 (accessed Sept 1, 2016).
9. Lang, T, Ebola: embed research in outbreak response. Nature 524 (2015), 29–31.
10. van Griensven, J, De Weiggheleire, A, Delamou, A, et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource constrained settings: a perspective from the field. Clin Infect Dis 62 (2015), 69–74.
11. Rid, A, Emanuel, EJ, Ethical considerations of experimental interventions in the Ebola outbreak. Lancet 384 (2014), 1896–1899.
12. World Health Organization. Ethical considerations for use of unregistered interventions for Ebola viral disease. http://apps.who.int/iris/bitstream/10665/130997/1/WHO_HIS_KER_GHE_14.1_eng.pdf, 2014 (accessed March 1, 2016).
13. WHO Ebola Response Team. Ebola virus disease in west Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 371 (2014), 1481–1495.
14. WHO Ebola Response Team. Ebola virus disease among male and female persons in west Africa. N Engl J Med 374 (2016), 96–98.
15. WHO Ebola Response Team, Agua-Agum, J, Ariyarajah, A, et al. Ebola virus disease among children in west Africa. N Engl J Med 372 (2015), 1274–1277.
16. Fitzgerald, F, Naveed, A, Wing, K, et al. Ebola virus disease in children, Sierra Leone, 2014–2015. Emerg Infect Dis 22 (2016), 1769–1777.
17. Bah, EI, Lamah, M-C, Fletcher, T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372 (2015), 40–47.
18. Fitzpatrick, G, Vogt, F, Moi Gbabai, OB, et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontières Ebola case management centre, Kailahun, Sierra Leone, June–October, 2014. J Infect Dis 212 (2015), 1752–1758.
19. Schieffelin, JS, Shaffer, JG, Goba, A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371 (2014), 2092–2100.
20. Yan, T, Mu, J, Qin, E, et al. Clinical characteristics of 154 patients suspected of having Ebola virus disease in the Ebola holding center of Jui Government Hospital in Sierra Leone during the 2014 Ebola outbreak. Eur J Clin Microbiol Infect Dis 34 (2015), 2089–2095.
21. Black, BO, Caluwaerts, S, Achar, J, Ebola viral disease and pregnancy. Obstet Med 8 (2015), 108–113.
22. Oduyebo, T, Pineda, D, Lamin, M, Leung, A, Corbett, C, Jamieson, DJ, A pregnant patient with Ebola virus disease. Obstet Gynecol 126 (2015), 1273–1275.
23. Caluwaerts, S, Fautsch, T, Lagrou, D, et al. Dilemmas in managing pregnant women with Ebola: 2 case reports. Clin Infect Dis 62 (2016), 903–905.
24. WHO. Interim guidance: clinical care for survivors of Ebola virus disease. http://apps.who.int/iris/bitstream/10665/204235/1/WHO_EVD_OHE_PED_16.1_eng.pdf, 2016 (accessed March 30, 2016).
25. Report of an International Commission. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56 (1978), 271–293.
26. Ebola haemorrhagic fever in Sudan, 1976, Report of a WHO/International study team. Bull World Health Organ 56 (1978), 247–270.
27. Barry, MÉ Touré A, Traoré FÉ et al. Clinical predictors of mortality in patients with Ebola virus disease. Clin Infect Dis 60 (2015), 1821–1824.
28. Barry, M, Traoré FA, Sako, FB, et al. Ebola outbreak in Conakry, Guinea: epidemiological, clinical, and outcome features. Med Mal Infect 44 (2014), 491–494.
29. Kreuels, B, Wichmann, D, Emmerich, P, et al. A case of severe Ebola virus infection complicated by Gram-negative septicemia. N Engl J Med 271 (2014), 2394–2401.
30. Liddell, AM, Davey, RT Jr, Mehta, AK, et al. Characteristics and clinical management of a cluster of 3 patients with Ebola virus disease, including the first domestically acquired cases in the United States. Ann Intern Med 163 (2015), 81–90.
31. Dietz, PM, Jambai, A, Paweska, JT, Yoti, Z, Ksiazek, TG, Epidemiology and risk factors for Ebola virus disease in Sierra Leone— 23 May 2014 to 31 January 2015. Clin Infect Dis 61 (2015), 1648–1654.
32. WHO Ebola Response Team, Agua-Agum, J, Ariyarajah, A, et al. West African Ebola epidemic after one year—slowing but not yet under control. N Engl J Med 372 (2015), 584–587.
33. Lado, M, Walker, NF, Baker, P, et al. Clinical features of patients isolated for suspected Ebola virus disease at Connaught Hospital, Freetown, Sierra Leone: a retrospective cohort study. Lancet Infect Dis 15 (2015), 1024–1033.
34. Hunt, L, Gupta-Wright, A, Simms, V, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis 15 (2015), 1292–1299.
35. Tiffany, A, Vetter, P, Mattia, J, et al. Ebola virus disease complications as experienced by survivors in Sierra Leone. Clin Infect Dis 62 (2016), 1360–1366.
36. Nanyonga, M, Saidu, J, Ramsay, A, Shindo, N, Bausch, DG, Sequelae of Ebola virus disease, Kenema District, Sierra Leone. Clin Infect Dis 62 (2016), 125–126.
37. Epstein, L, Wong, KK, Kallen, AJ, Uyeki, TM, Post-Ebola signs and symptoms in US survivors. N Engl J Med 373 (2015), 2484–2486.
38. Qureshi, AI, Chughtai, M, Loua, TO, et al. Study of Ebola virus disease survivors in Guinea. Clin Infect Dis 61 (2015), 1035–1042.
39. Vetter, P, Kaiser, L, Schibler, M, Ciglenecki, I, Bausch, DG, Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis 16 (2016), e82–e91.
40. Sagui, E, Janvier, F, Baize, S, et al. Severe Ebola virus infection with encephalopathy: evidence for direct virus involvement. Clin Infect Dis 61 (2015), 1627–1628.
41. de Greslan, T, Billhot, M, Rousseau, C, et al. Ebola virus-related encephalitis. Clin Infect Dis 63 (2016), 1076–1078.
42. Chertow, DS, Nath, A, Suffredini, AF, et al. Severe meningoencephalitis in a case of Ebola virus disease: a case report. Ann Intern Med 165 (2016), 301–304.
43. Scott, JT, Sesay, FR, Massaquoi, TA, Idriss, BR, Sahr, F, Semple, MG, Post-Ebola syndrome, Sierra Leone. Emerg Infect Dis 22 (2016), 641–646.
44. Mattia, JG, Vandy, MJ, Chang, JC, et al. Early clinical sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. Lancet Infect Dis 16 (2016), 331–338.
45. Cellarier, G, Bordes, J, De Greslan, T, et al. Inappropriate bradycardia in Ebola virus disease. Med Sante Trop 26 (2016), 283–286.
46. Sueblinvong, V, Johnson, DW, Weinstein, GL, et al. Critical care for multiple organ failure secondary to Ebola virus disease in the United States. Crit Care Med 43 (2015), 2066–2075.
47. Chertow, DS, Childs, RW, Arai, AE, Davey, RT Jr, Cardiac MRI findings suggest myocarditis in severe Ebola virus disease. JACC Cardiovasc Imaging, 2016, 10.1016/j.jcmg.2016.06.004 published online Aug 11.
48. Wolf, T, Kann, G, Becker, S, et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 385 (2015), 1428–1435.
49. de Wit, E, Kramer, S, Prescott, J, et al. Clinical chemistry of patients with Ebola in Monrovia, Liberia. J Infect Dis 214:suppl 3 (2016), S303–S307.
50. Sissoko, D, Laouenan, C, Folkesson, E, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med, 13, 2016, e1001967.
51. van Griensven, J, Bah, EI, Haba, N, et al. Electrolyte and metabolic disturbances in Ebola patients during a clinical trial, Guinea, 2015. Emerg Infect Dis 22 (2016), 2120–2127.
52. Richardson, ET, Kelly, JD, Barrie, MB, et al. Minimally symptomatic infection in an Ebola ‘hotspot': a cross-sectional serosurvey. PLoS Negl Trop Dis, 10, 2016, e0005087.
53. Moyen, N, Thirion, L, Emmerich, P, et al. Risk factors associated with Ebola and Marburg viruses seroprevalence in blood donors in the Republic of Congo. PLoS Negl Trop Dis, 9, 2015, e0003833.
54. Schoepp, RJ, Rossi, CA, Khan, SH, Goba, A, Fair, JN, Undiagnosed acute viral febrile illnesses, Sierra Leone. Emerg Infect Dis 20 (2014), 1176–1182.
55. WHO Ebola Response Team, Agua-Agum, J, Allegranzi, B, et al. After Ebola in west Africa—unpredictable risks, preventable epidemics. N Engl J Med 375 (2016), 587–596.
56. Ansumana, R, Jacobsen, KH, Sahr, F, et al. Ebola in Freetown area, Sierra Leone—a case study of 581 patients. N Engl J Med 372 (2015), 587–588.
57. Uyeki, TM, Mehta, AK, Davey, RT Jr, et al. Clinical management of Ebola virus disease in the United States and Europe. N Engl J Med 374 (2016), 636–646.
58. Feldmann, H, Geisbert, TW, Ebola haemorrhagic fever. Lancet 377 (2011), 849–862.
59. Falasca, L, Agrati, C, Petrosillo, N, et al. Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. Cell Death Differ 22 (2015), 1250–1259.
60. Martines, RB, Ng, DL, Greer, PW, Rollin, PE, Zaki, SR, Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol 235 (2015), 153–174.
61. Bordes, J, Janvier, F, Aletti, M, et al. Organ failures on admission in patients with Ebola virus disease. Intensive Care Med 41 (2015), 1504–1505.
62. Cournac, JM, Karkowski, L, Bordes, J, et al. Rhabdomyolysis in Ebola virus disease. Results of an observational study in a treatment center in Guinea. Clin Infect Dis 62 (2016), 19–23.
63. Janvier, F, Gorbatch, S, Queval, L, et al. Difficulties of interpretation of Zaire Ebola Virus PCR results and implication in the field. J Clin Virol 67 (2015), 36–37.
64. Zhang, X, Rong, Y, Sun, L, et al. Prognostic analysis of patients with Ebola virus disease. PLoS Negl Trop Dis, 9, 2015, e0004113.
65. Qin, E, Bi, J, Zhao, M, et al. Clinical features of patients with Ebola virus disease in Sierra Leone. Clin Infect Dis 61 (2015), 491–495.
66. Petrosillo, N, Nicastri, E, Lanini, S, et al. Ebola virus disease complicated with viral interstitial pneumonia: a case report. BMC Infect Dis, 15, 2015, 432.
67. Chertow, DS, Kleine, C, Edwards, JK, Scaini, R, Giuliani, R, Sprecher, A, Ebola virus disease in west Africa—clinical manifestations and management. N Engl J Med 371 (2014), 2054–2057.
68. Wilson, AJ, Martin, DS, Maddox, V, et al. Thromboelastography in the management of coagulopathy associated with Ebola virus disease. Clin Infect Dis 62 (2016), 610–612.
69. Jacobs, M, Rodger, A, Bell, DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 388 (2016), 498–503.
70. Lanini, S, Portella, G, Vairo, F, et al. Blood kinetics of Ebola virus in survivors and nonsurvivors. J Clin Invest 125 (2015), 4692–4698.
71. van Griensven, J, Edwards, T, de Lamballerie, X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374 (2016), 33–42.
72. Li, J, Duan, HJ, Chen, HY, et al. Age and Ebola viral load correlate with mortality and survival time in 288 Ebola virus disease patients. Int J Infect Dis 42 (2016), 34–39.
73. Faye, O, Andronico, A, Faye, O, et al. Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study. PLoS Med, 12, 2015, e1001908.
74. Baize, S, Leroy, EM, Georges, AJ, et al. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 128 (2002), 163–168.
75. McElroy, AK, Erickson, BR, Flietstra, TD, et al. Biomarker correlates of survival in pediatric patients with Ebola virus disease. Emerg Infect Dis 20 (2014), 1683–1690.
76. McElroy, AK, Harmon, JR, Flietstra, TD, et al. Kinetic analysis of biomarkers in a cohort of US patients with Ebola virus disease. Clin Infect Dis 63 (2016), 460–547.
77. Rosenke, K, Adjemian, J, Munster, VJ, et al. Plasmodium parasitemia associated with increased survival in Ebola virus-infected patients. Clin Infect Dis 63 (2016), 1026–1033.
78. Kerber, R, Krumkamp, R, Diallo, B, et al. Analysis of diagnostic findings from the European mobile laboratory in Gueckedou, Guinea, March 2014 through March 2015. J Infect Dis 214:suppl 3 (2016), S250–S257.
79. Schwarze-Zander, C, Blackard, JT, Rockstroh, JK, Role of GB virus C in modulating HIV disease. Expert Rev Anti Infect Ther 10 (2012), 563–572.
80. Lamontagne, F, Clément, C, Fletcher, T, Jacob, ST, Fischer, WA 2nd, Fowler, RA, Doing today's work superbly well—treating Ebola with current tools. N Engl J Med 371 (2014), 1565–1566.
81. WHO. Manual for the care and management of patients in Ebola care units/Community Care Centres: interim emergency guidance, January 2015. http://apps.who.int/iris/handle/10665/149781, 2015 (accessed June 11, 2016).
82. Médécins Sans Frontières. Filovirus haemorrhagic fever guideline. http://www.slamviweb.org/es/ebola/FHFfinal.pdf, 2008 (accessed June 12, 2016).
83. Roberts, I, Perner, A, Ebola virus disease: clinical care and patient-centred research. Lancet 384 (2014), 2001–2002.
84. Maitland, K, Babiker, A, Kiguli, S, Molyneux, E, FEAST Trial Group. The FEAST trial of fluid bolus in African children with severe infection. Lancet 379 (2012), 613–614.
85. Kreuels, B, Addo, MM, Schmiedel, S, Severe Ebola virus infection complicated by Gram-negative septicemia. N Engl J Med, 372, 2015, 1377.
86. Hellman, J, Addressing the complications of Ebola and other viral hemorrhagic fever infections: using insights from bacterial and fungal sepsis. PLoS Pathog, 11, 2015, e1005088.
87. Trehan, I, Kelly, T, Marsh, RH, George, PM, Callahan, CW, Moving towards a more aggressive and comprehensive model of care for children with Ebola. J Pediatr 170 (2016), 28–33.
88. Clark, DV, Kibuuka, H, Millard, M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 15 (2015), 905–912.
89. Rowe, AK, Bertolli, J, Khan, AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179:suppl 1 (1999), S28–S35.
90. Mohammed, A, Sheikh, TL, Gidado, S, et al. An evaluation of psychological distress and social support of survivors and contacts of Ebola virus disease infection and their relatives in Lagos, Nigeria: a cross sectional study—2014. BMC Public Health, 15, 2015, 824.
91. Varkey, JB, Shantha, JG, Crozier, I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 372 (2015), 2423–2427.
92. Shantha, JG, Crozier, I, Varkey, JB, et al. Long-term management of panuveitis and iris heterochromia in an Ebola survivor. Ophthalmology 123 (2016), 2626–2628.
93. Bower, H, Smout, E, Bangura, MS, et al. Deaths, late deaths, and role of infecting dose in Ebola virus disease in Sierra Leone: retrospective cohort study. BMJ, 353, 2016, i2403.
94. Thorson, A, Formenty, P, Lofthouse, C, Broutet, N, Systematic review of the literature on viral persistence and sexual transmission from recovered Ebola survivors: evidence and recommendations. BMJ Open, 6, 2016, e008859.
95. Chughtai, AA, Barnes, M, Macintyre, CR, Persistence of Ebola virus in various body fluids during convalescence: evidence and implications for disease transmission and control. Epidemiol Infect 144 (2016), 1652–1660.
96. Soka, MJ, Choi, MJ, Baller, A, et al. Prevention of sexual transmission of Ebola in Liberia through a national semen testing and counselling programme for survivors: an analysis of Ebola virus RNA results and behavioural data. Lancet Glob Health 4 (2016), e736–e743.
97. Deen, GF, Knust, B, Broutet, N, et al. Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. N Engl J Med, 2015, 10.1056/NEJMoa1511410 published online Oct 14.
98. Baggi, FM, Taybi, A, Kurth, A, et al. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. Euro Surveill 19 (2014), 1–4.
99. Bower, H, Grass, JE, Veltus, E, et al. Delivery of an Ebola virus-positive stillborn infant in a rural community health center, Sierra Leone, 2015. Am J Trop Med Hyg 94 (2016), 417–419.
100. Lyon, GM, Mehta, AK, Varkey, JB, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med 371 (2014), 2402–2409.
101. Bausch, DG, Towner, JS, Dowell, SF, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196:suppl 2 (2007), S142–S147.
102. Rodriguez, LL, De Roo, A, Guimard, Y, et al. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179:suppl 1 (1999), S170–S176.
103. Diallo, B, Sissoko, D, Loman, NJ, et al. Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clin Infect Dis 63 (2016), 1353–1356.
104. Mate, SE, Kugelman, JR, Nyenswah, TG, et al. Molecular evidence of sexual transmission of Ebola virus. N Engl J Med 373 (2015), 2448–2454.
105. Fallah, MP, Skrip, LA, Dahn, BT, et al. Pregnancy outcomes in Liberian women who conceived after recovery from Ebola virus disease. Lancet Glob Health 4 (2016), e678–e679.
106. Sonnenberg, P, Field, N, Sexual and mother-to-child transmission of Ebola virus in the postconvalescent period. Clin Infect Dis 60 (2015), 974–975.
107. Mupapa, K, Massamba, M, Kibadi, K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 179:suppl 1 (1999), S18–S23.
108. PREVAIL II Writing Group, Multi-National PREVAIL II Study Team. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med 375 (2016), 1448–1456.
109. Dunning, J, Sahr, F, Rojek, A, et al. Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial. PLoS Med, 13, 2016, e1001997.
110. Dunning, J, Kennedy, SB, Antierens, A, et al. Experimental treatment of Ebola virus disease with brincidofovir. PLoS One, 11, 2016, e0162199.
111. van Griensven, J, Edwards, T, Baize, S, Ebola-Tx Consortium. Efficacy of convalescent plasma in relation to dose of Ebola virus antibodies. N Engl J Med 375 (2016), 2307–2309.
112. Mora-Rillo, M, Arsuaga, M, Ramirez-Olivencia, G, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med 3 (2015), 554–562.
113. Schibler, M, Vetter, P, Cherpillod, P, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis 15 (2015), 1034–1040.
114. Bai, CQ, Mu, JS, Kargbo, D, et al. Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)—Sierra Leone, 2014. Clin Infect Dis 63 (2016), 1288–1294.
115. WHO. Ebola vaccines, therapies, and diagnostics: questions and answers. http://www.who.int/medicines/emp_ebola_q_as/en/, 2015 (accessed Feb 1, 2016).
116. Fedson, DS, Jacobson, JR, Rordam, OM, Opal, SM, Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers. MBio, 6, 2015, e00716.
117. Gignoux, E, Azman, AS, de Smet, M, et al. Effect of artesunate–amodiaquine on mortality related to Ebola virus disease. N Engl J Med 374 (2016), 23–32.
118. Madrid, PB, Chopra, S, Manger, ID, et al. A systematic screen of FDA-approved drugs for inhibitors of biological threat agents. PLoS One, 8, 2013, e60579.
119. Thi, EP, Mire, CE, Lee, AC, et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 521 (2015), 362–365.
120. Qiu, X, Wong, G, Audet, J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514 (2014), 47–53.
121. Mendoza, EJ, Qiu, X, Kobinger, GP, Progression of Ebola therapeutics during the 2014–2015 outbreak. Trends Mol Med 22 (2016), 164–173.
122. WHO. Ebola R&D landscape of clinical candidates and trials. http://www.who.int/medicines/ebola-treatment/EbolaR_D_public-report_updt2015.pdf?ua=1, October 2015 (accessed Feb 1, 2016).
123. Henao-Restrepo, AM, Preziosi, MP, Wood, D, Moorthy, V, Kieny, MP, WHO Ebola Research Development Team. On a path to accelerate access to Ebola vaccines: the WHO's research and development efforts during the 2014–2016 Ebola epidemic in west Africa. Curr Opin Virol 17 (2016), 138–144.
124. Henao-Restrepo, AM, Longini, IM, Egger, M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
125. WHO. International Clinical Trials Registry Platform—PACTR201503001057193. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=PACTR201503001057193, 2016 (accessed Oct 20, 2016).
126. Ebola ça Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ, 351, 2015, h3740.
127. Agnandji, ST, Huttner, A, Zinser, ME, et al. Phase 1 Trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374 (2016), 1647–1660.
128. Cnops, L, Gerard, M, Vandenberg, O, et al. Risk of misinterpretation of Ebola virus PCR results after rVSV ZEBOV-GP vaccination. Clin Infect Dis 60 (2015), 1725–1726.
129. Tapia, MD, Sow, SO, Lyke, KE, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 16 (2016), 31–42.
130. De Santis, O, Audran, R, Pothin, E, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis 16 (2016), 311–320.
131. Ledgerwood, JE, Sullivan, NJ, Graham, BS, Chimpanzee adenovirus vector Ebola vaccine—preliminary report. N Engl J Med, 373, 2015, 776.
132. Ewer, K, Rampling, T, Venkatraman, N, et al. A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA. N Engl J Med 374 (2016), 1635–1646.
133. Milligan, ID, Gibani, MM, Sewell, R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified Vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 315 (2016), 1610–1623.
134. Bausch, DG, Rojek, A, West Africa 2013: re-examining Ebola. Microbiol Spectr, 4, 2016 EI10-0022-2016.
135. WHO. Meeting summary of the WHO consultation on potential Ebola therapies and vaccines, 2014, World Health Organization, Geneva.
136. Henao-Restrepo, AM, Camacho, A, Longini, IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 389 (2016), 505–518.